DOCSLIB.ORG

Group Presentations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Group Presentations Exercise 1 – AMR tools Group presentations NOTE: This material is only intended for the EURL-AR training course 2019 participants as a follow-up to the discussions we had in the classroom and any use outside its scope is not under the responsibility of the EURL-AR Date DTU Title 1 Before we start… • It was on purpose not to give too detailed instructions about the tools of Exercise 1 and to let you look at the different tools and trigger your curiosity (last year we went step by step – please look at the manual from last year/send me an email if you would like to receive it) • Do not be frustrated if you did not reach the end of the exercises – it was not meant to happen for all, however each step represented a potential new knowledge gained and you should focus on what you have learned Date DTU Title 2 Isolate 1 – Campylobacter jejuni Date DTU Title 3 Exercise 1 Group 1 & 19: Daniel, Mike and Deirdre Species ID: Isolate number 1: Campylobacter jejuni Date DTU Title QC Fasta/Fastq • FastQC (free tool) –2.3 million reads, trimmed data all close to Q30 • Bbmap (free tool) – showed quality of assembly N50: 333 kb, Contigs: 13, Longest contig 646 kb, total number bps 1.7 Mb • Species finder (CGE): Campylobacter jejuni Conclusion: Species correct and data of good quality Note the freely available tools for estimating sequence quality Date DTU Title Bioinformatics tools/not used and why Successfully used • ResFinder-3 –user friendly, familiar with, reputable • ResFinder-4 - user friendly, familiar with, reputable • CARD – user friendly Tried • ABRES Finder – input amino acid sequence • ABRICATE – need to download and cannot on Labtop • ARDB – no longer maintained, last updated 2009 • ARG-ANNOT - DISCONTINUED • ARIBA - need to download and cannot on Labtop • NCBI AMRFinder – looked at it but difficult to navigate and see how to upload files • Noradab – could not upload files, had to copy the fasta sequence Date DTU Title Results Observed Predicted resistance resistance STRAIN 1 Tools phenotype phenotype RESFIND RESFIND RESFIND AMR gene or ER 3.2 ER 3.2 ER 4.0 mutation FASTA FASTQ FASTA CARD blaOXA-461 yes yes yes yes Natural gene in Campy Intrinsic resistance? tet(W/N/ Tetracycline tet(O/32/O) yes yes yes W) Tetracycline resistance resistance Ciprofloxacin Ciprofloxacin gyrA p.T86I (known) yes yes yes yes resistance resistance 4 unknown mutations in gyrA yes yes no 14 unknown mutations in 23S yes yes no ResFinder 4.0 – submitted fastq files but job failed Date DTU Title Date DTU Title Date DTU Title ResFinder 3.2 Fasta Date DTU Title Difference between Resfinder and Card Date DTU Title ResFinder vs CARD % Identity CARD ResFinder tet(W/N/W) 68.34 tet(O/32/O) 100 Conclusion: • If using CARD only Tet resistance could have been missed/unsure how to interpret • Output from CARD very fast • CARD showed gyrA present, not 100% (99.5%) • CARD does not show unknown mutations • Information provided by ResFinder more complete Date DTU Title Phenotypic results for isolate 1 ciprofloxacin erythromycin gentamicin nalidixic acid streptomycin tetracycline MIC: 16.0 > 0.5 MIC: <=1.0 > 4.0 MIC: 0.5 > 2.0 MIC: 8.0 > 16.0 MIC: 1.0 > 4.0 MIC: 32.0 > 1.0 Note that there seems to be genotype-phenotype discordance for nalidixic acid (the isolate is genotypically resistant (gyrA T86I) and phenotypically susceptible). However the nalidixic acid MIC measured phenotypically is close to the ECOFF and the isolate is also ciprofloxacin-resistant thus the observed discordance is likely due to limitations in the broth microdilution method in which a two-fold dilution difference between repeated measurements is considered acceptable. Date DTU Title Does the predicted phenotype match the phenotype measured in the laboratory? Yes • Phenotype measured in the Laboratory: CIP and TET resistant • Predicted phenotype based on bioinformatics analysis: Ciprofloxacin and Tetracycline resistance Date DTU Title Isolate 2 – Campylobacter jejuni Date DTU Title 15 Group 9 Isolate 2 Campylobacter jejuni • ResFinder 4 and 3.2, CARD and Kmer Resistance 2.2. • Reasons: is curated, updated regularly and used in many recent research works. CARD is having chromosomal mutations, more information can be generated. • Differences in the results are observed between different bioinformatics tools, • Reasons: different pipelines, quality parameters for selection might differ % of coverage and identity, FASTA Vs FASTQ data, different assemblers, some are not including the efflux pumps Note that ResFinder also includes PointFinder for detection of chromosomal mutations but the user needs to actively select this option in the front page Date DTU Title There is genotype-phenotype discordance for tetracycline since CARD Resfinder 4 ResFinder 3.2 Kmer genotypic detection of tetO would lead to prediction of AMR gene or (Fasta (FASTQ/FAS (FASTQ/FA (FASTA/FAST mutation ) TA) STA) tetracyclineQ) resistance whereas Predicted the phenotypic R test yielded a OXA460 yes No/no Yes/yestetracyclineYes/yes susceptible isolate.cephalosporin, However, tetO Beta-lactamhad <100% identity to the gene in the databaseMulticlass thus we(including cannot exclude macrolide fluoroquinolone, mutation(s) leading to stop codonaminoglycoside, and thus lack of tetO cmeR yes No/no No/no expression.No/no This could be easilycephalosporin, investigated bytetracycline) analyzing the tetO yes No/yes Yes/yes Yes/yes tetracycline Campylobacter jejuni sequence although this ‘manual’ analysis would not be very gyrA conferring easily applicable when analyzing large datasets. Furthermore, resistance to fluoroquinolones yes No/yes Yes/yesthe tetracyclineNo/no MIC measuredfluoroquinolone phenotypically is close to the ECOFF the broth microdilution method has limitations by which a two-fold dilution difference between repeated measurements is Phenotipic considered acceptable Isolate ciprofloxacin erythromycin gentamicin nalidixic acid streptomycin tetracycline 2 MIC: 16.0 > 0.5 MIC: <=1.0 > 4.0 MIC: 0.25 > 2.0 MIC: >64.0 > 16.0 MIC: 0.5 > 4.0 MIC: <=0.5 > 1.0 This discrepancy is unusual and will be further examined by ResFinder 4 developers Date DTU Title Isolate 3 – Escherichia coli Date DTU Title 18 GROUPS 3 and 17 Exercise 1 Date DTU Title • Isolate Nr. 3 • Escherichia coli • TOOLS USED ResFinder (usually used, reference method for comparison) – FASTA, FASTQ CARD (suggested one) – FASTA • Differences between FASTA and FASTQ input in the same tool but it didn’t change the predicted phenotype • Different output – table, or .txt file you need to figure out a way to open Date DTU Title RESULTS • CARD gave lot more hits mainly in antibiotic efflux mechanisms – CARD has more data WHY? • different approach – acquired or intrinsic, plasmid or chromosomal, functional or not • Different nomenclature (ampC – not normaly expressed in the chromosome except for a promotor mutation, expressed only on plasmid) • Difference in phenotype prediction between tools: CARD gave hits we cannot predict the phenotype with ResFinder gives hits only with a predictable phenotype • Both give mutated genes Date DTU Title RESULTS • CARD gave lot more hits mainly in antibiotic efflux mechanisms – CARD has more data WHY? • different approach – acquired or intrinsic, plasmid or chromosomal, functional or not • Different nomenclature (ampC – not normaly expressed in the chromosome except for a promotor ampC is a chromosomal gene normally repressed in E. coli. Chromosoaml mutation, expressed only on plasmid) mutations can lead to removal of such repression and expression of the chromosomal ampC that encodes an AmpC-type beta-lactamase. • Difference in phenotype prediction between tools: CARD gave hits we cannot predictOf the note, phenotype there are withmany genes other than chromosomal ampC that can encode AmpC-type beta-lactamases and they are usually plasmid- ResFinder gives hits only with a predictablemediated in phenotype E. coli • Both give mutated genes Date DTU Title RESULTS • CARD gave lot more hits mainly in antibiotic efflux mechanisms – CARD has more data WHY? • different approach – acquired or intrinsic, plasmid or chromosomal, functional or not • Different nomenclature (ampC – not normaly expressed in the chromosome except for a promotor mutation, expressed only on plasmid) • Difference in phenotype prediction between tools: CARD gave hits we cannot predict the phenotype with ResFinder gives hits only with a predictable phenotype • Both give mutated genes Date DTU Title CONCORDANCE • The predicted and measured phenotypes basicaly matched • CARD found other genes but could not predict the phenotype using them • Active or inactive genes, selective pressure, mutations Date DTU Title Isolate 4 – Escherichia coli Date DTU Title 25 Exploring the jungle of AMR detection tool Groups 7, 13 Exercise 1 • Specie ID isolate Escherichia coli, isolate code 4 • Which bioinformatics tools did you use and why? As a beginners => tools recommended in manual: ResFinder and CARD Date DTU Title Please note: even when using the same database, different Groups 7, 13 tools may give different results because: - The algorithm used by different tools is different Exercise 1 - It often happens that updates made in one database are not immediately captured by all tools using such database • Which bioinformatics tools did you not use and why? dedicated to another specific species e.g. Staphylococcus - SCCmecFinder-1.2 Tools based on the same databases as those that we used Those that require access account Date DTU Title Escherichia coli, isolate code 4 depending on used tool results differed Tools used Predicted resistance phenotype Observed resistance phenotype AMR gene/mutation ResFinder‐3CARD blaTEM‐1B yes yes (perfect match) Ampicillin, Cefotaxime,Ceftazidime Ampicillin, Cefotaxime,Ceftazidime tet(A) yes (99,92% identity) yes (strict match) Tetracycline Tetracycline R (MIC: >64.0 > 8.0) ampC promoter n.42C>T yes no Ampicillin, Cefotaxime, Ceftazidime Ampicillin, Cefotaxime, Ceftazidime gyrA p.D87N GAC‐>AAC yes no Ciprofloxacin, Nalidix acid Ciprofloxacin, Nalidix acid yes => Warning: gene is missing from Notes mdf(A) no Macrolide not provided, not tested? file.
Load more

Recommended publications
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Alphataxin, an Orally Available Small Molecule, Decreases LDL Levels in Mice As a Surrogate for the LDL-Lowering Activity of Alpha-1 Antitrypsin in Humans
    ORIGINAL RESEARCH published: 09 June 2021 doi: 10.3389/fphar.2021.695971 Alphataxin, an Orally Available Small Molecule, Decreases LDL Levels in Mice as a Surrogate for the LDL-Lowering Activity of Alpha-1 Antitrypsin in Humans Cynthia L. Bristow 1,2* and Ronald Winston 1,2 1Alpha-1 Biologics, Long Island High Technology Incubator, Stony Brook University, Stony Brook, NY, United States, 2Institute for Human Genetics and Biochemistry, Vesenaz, Switzerland Edited by: Guanglong He, University of Wyoming, United States The abundant blood protein α1-proteinase inhibitor (α1PI, Alpha-1, α1-antitrypsin, Reviewed by: SerpinA1) is known to bind to the active site of granule-associated human leukocyte Hua Zhu, α The Ohio State University, elastase (HLE-G). Less well known is that binding of 1PI to cell surface HLE (HLE-CS) United States induces lymphocyte locomotion mediated by members of the low density lipoprotein Adam Chicco, receptor family (LDL-RFMs) thereby facilitating low density lipoprotein (LDL) clearance. LDL Colorado State University, United States and α1PI were previously shown to be in negative feedback regulation during transport and *Correspondence: clearance of lipoproteins. Further examination herein of the influence of α1PI in lipoprotein Cynthia L. Bristow regulation using data from a small randomized, double-blind clinical trial shows that cynthia.bristow@ α alpha1biologics.com treatment of HIV-1-infected individuals with 1PI plasma products lowered [email protected] apolipoprotein and lipoprotein levels including LDL. Although promising, plasma- orcid.org/0000-0003-1189-5121 purified α1PI is limited in quantity and not a feasible treatment for the vast number of Specialty section: people who need treatment for lowering LDL levels.
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • Identification of Leishmania Donovani Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture
    bioRxiv preprint doi: https://doi.org/10.1101/716134; this version posted July 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Identification of Leishmania donovani inhibitors from pathogen box compounds of Medicine for Malaria Venture Markos Tadele1¶, Solomon M. Abay2¶*, Eyasu Makonnen2,4, Asrat Hailu3 1 Ethiopian institute of agricultural research, Animal health research program, Holetta, Ethiopia 2Department of Pharmacology and clinical pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia 3Department of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia 4Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT Africa), College of Health Sciences, Addis Ababa University * Corresponding author Email: [email protected], [email protected] ¶ These authors contributed equally to this work. Author Contributions Conceptualization and design the experiment: MT, SMA, EM, AH Investigation: MT, SMA, AH Data analysis: MT, SMA Funding acquisition and reagents contribution: SMA, AH Supervision: SMA, EM, AH Writing – original draft: MT Writing – review & editing: MT, SMA, EM, AH 1 | P a g e bioRxiv preprint doi: https://doi.org/10.1101/716134; this version posted July 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
    [Show full text]
  • The Nitroimidazole Family of Drugs
    Br J Vener Dis: first published as 10.1136/sti.54.2.69 on 1 April 1978. Downloaded from British Journal of Venereal Diseases, 1978, 54, 69-71 Editorial The nitroimidazole family of drugs In 1955 an antibiotic complex isolated from a operative infection caused by susceptible anaerobes, strain of Streptomyces on the island of Reunion particularly in gynaecological surgery, appendi- was found by research workers of Rhone-Poulenc in cectomy, and colonic surgery. Paris to contain a trichomonacidal antibiotic- Real innovations in chemotherapy, such as azomycin. It had previously been isolated in Japan metronidazole, always attract attention from other (Maeda et al., 1953) and identified as 2-nitroimi- research groups. Although interest was slow to dazole (Ia see Table) (Nakamura, 1955). At the develop, research workers have sought analogous, time, and for some years after, this remarkably structurally-modified compounds which might afford simple compound defied synthesis, but it stimulated some advantage in clinical use-for example, the workers at Rhone-Poulenc to prepare and test greater potency, better tolerance and freedom from the activity of the more readily accessible isomeric side effects, a broader spectrum of action, a longer 5-nitroimidazoles (II). It was their good fortune in duration of action, or in some other characteristic. 1957 to find that these isomers were more active This effort has been concerned with important antiprotozoal agents than the natural product veterinary uses of 5-nitroimidazoles as well as the (Cosar and Julou, 1959). In a series of 150 related applications in human medicine. compounds, the one with a P-hydroxyethyl group Metronidazole has been a difficult target to in the 1-position gave the best compromise between improve upon, but several other drugs of this activity and toxicity and this brand of metroni- chemical family have been introduced to clinical dazole was introduced as Flagyl.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Beta Lactam Antibiotics Penicillins Pharmaceutical
    BETA LACTAM ANTIBIOTICS PENICILLINS PHARMACEUTICAL CHEMISTRY II PHA386 PENICILLINS Penicillin was discovered in 1928 by Scottish scientist Alexander Fleming, who noticed that one of his experimental cultures of staphylococcus was contaminated with mold (fortuitous accident), which caused the bacteria to lyse. Since mold belonged to the family Penicillium (Penicillium notatum), he named the antibacterial substance Penicillin. Penicillin core structure CHEMICAL STRUCTURE PENAM RING PENICILLIN G 6-APA • 6-APA is the chemical compound (+)-6-aminopenicillanic acid. • It is the core of penicillin. PENAM RING 5 1 • 7-oxo-1- thia-4-azabicylo [3,2,0] heptane 6 2 7 3 4 PENICILLANIC ACID • 2,2–dimethyl penam –3– carboxylic acid • 2,2-dimethyl-7-oxo-1- thia-4-azabicylo [3,2,0]heptane -3-carboxylic acid 6-AMINO PENICILLANIC ACID (6-APA) • 6-amino-2,2–dimethyl penam –3– carboxylic acid • 6-amino-2,2-dimethyl-7-oxo-1- thia-4-azabicylo [3,2,0] heptane-3-carboxylic acid PENISILLIN G (BENZYL PENICILLIN) O S CH3 CH2 C NH CH3 N O COO-K+ 6-(2-Phenylacetamino) penicillanic acid potassium salt PENICILLIN G PROCAINE O C 2 H 5 ‐ H N C H 2 C H 2 O C N H 2 C 2 H 5 PENICILLIN G BENZATHINE ‐ ‐ C H 2 C H 2 H N C H 2 C H 2 N H H H PENICILLIN V (PHENOXYMETHYL PENICILLIN) PHENETHICILLIN PROPACILLIN METHICILLIN SODIUM OCH3 S CH3 CONH CH3 N - + OCH3 O COO Na 6-[(2,6-dimethoxybenzoyl)amino] penicillanic acid sodium salt NAFCILLIN SODIUM 6-(2-ethoxy-1-naphtylcarbonylamino) penicillanic acid sodium salt OXACILLIN SODIUM 6-[(5-methyl-3-phenylizoxazole-4-yl)-carbonylamino] sodium
    [Show full text]
  • 2-Substituted Methyl Penam Derivatives 2-Substituierte Methyl-Penam-Derivate Dérivés 2-Substitués Du Méthyl Pénam
    (19) TZZ ZZ _T (11) EP 2 046 802 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: C07D 499/87 (2006.01) C07D 499/21 (2006.01) of the grant of the patent: C07D 499/28 (2006.01) C07D 499/32 (2006.01) 21.08.2013 Bulletin 2013/34 A61K 31/431 (2006.01) A61P 31/00 (2006.01) (21) Application number: 07804590.3 (86) International application number: PCT/IB2007/001941 (22) Date of filing: 11.07.2007 (87) International publication number: WO 2008/010048 (24.01.2008 Gazette 2008/04) (54) 2-SUBSTITUTED METHYL PENAM DERIVATIVES 2-SUBSTITUIERTE METHYL-PENAM-DERIVATE DÉRIVÉS 2-SUBSTITUÉS DU MÉTHYL PÉNAM (84) Designated Contracting States: • SRIRAM, Rajagopal AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Chennai, Tamil Nadu 600 119 (IN) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • PAUL-SATYASEELA, Maneesh SI SK TR Chennai, Tamil Nadu 600 119 (IN) • SOLANKI, Shakti, Singh (30) Priority: 12.07.2006 IN CH12172006 Chennai, Tamil Nadu 600 119 (IN) • DEVARAJAN, Sathishkumar (43) Date of publication of application: Chennai, Tamil Nadu 600 119 (IN) 15.04.2009 Bulletin 2009/16 (74) Representative: Murphy, Colm Damien et al (73) Proprietor: Allecra Therapeutics GmbH Ipulse 79539 Lörrach (DE) Carrington House 126-130 Regent Street (72) Inventors: London W1B 5SE (GB) • UDAYAMPALAYAM, Palanisamy, Senthilkumar Chennai, Tamil Nadu 600 119 (IN) (56) References cited: • GNANAPRAKASAM, Andrew EP-A1- 0 097 446 EP-A1- 0 367 124 Chennai, Tamil Nadu 600 119 (IN) JP-A- 60 215 688 US-A1- 2005 070 705 • GANAPATHY, Panchapakesan US-A1- 2005
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Evidence of Pyrimethamine and Cycloguanil Analogues As Dual Inhibitors of Trypanosoma Brucei Pteridine Reductase and Dihydrofolate Reductase
    pharmaceuticals Article Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase Giusy Tassone 1,† , Giacomo Landi 1,†, Pasquale Linciano 2,† , Valeria Francesconi 3 , Michele Tonelli 3 , Lorenzo Tagliazucchi 2 , Maria Paola Costi 2 , Stefano Mangani 1 and Cecilia Pozzi 1,* 1 Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018–2022, University of Siena, via Aldo Moro 2, 53100 Siena, Italy; [email protected] (G.T.); [email protected] (G.L.); [email protected] (S.M.) 2 Department of Life Science, University of Modena and Reggio Emilia, via Campi 103, 41125 Modena, Italy; [email protected] (P.L.); [email protected] (L.T.); [email protected] (M.P.C.) 3 Department of Pharmacy, University of Genoa, Viale Benedetto XV n.3, 16132 Genoa, Italy; [email protected] (V.F.); [email protected] (M.T.) * Correspondence: [email protected]; Tel.: +39-0577-232132 † These authors contributed equally to this work. Abstract: Trypanosoma and Leishmania parasites are the etiological agents of various threatening Citation: Tassone, G.; Landi, G.; neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, Linciano, P.; Francesconi, V.; Tonelli, and various types of leishmaniasis. Recently, meaningful progresses in the treatment of HAT, due to M.; Tagliazucchi, L.; Costi, M.P.; Trypanosoma brucei (Tb), have been achieved by the introduction of fexinidazole and the combination Mangani, S.; Pozzi, C. Evidence of therapy eflornithine–nifurtimox. Nevertheless, due to drug resistance issues and the exitance of Pyrimethamine and Cycloguanil animal reservoirs, the development of new NTD treatments is still required.
    [Show full text]